Show simple item record

dc.contributor.authorVickers, Mark A.
dc.contributor.authorWilkie, Gwen M.
dc.contributor.authorRobinson, Nicolas
dc.contributor.authorRivera, Nadja
dc.contributor.authorHaque, Tanzina
dc.contributor.authorCrawford, Dorothy H.
dc.contributor.authorBarry, Jacqueline
dc.contributor.authorFraser, Neil
dc.contributor.authorTurner, David M.
dc.contributor.authorRobertson, Victoria
dc.contributor.authorDyer, Phil
dc.contributor.authorFlanagan, Peter
dc.contributor.authorNewlands, Helen R.
dc.contributor.authorCampbell, John
dc.contributor.authorTurner, Marc
dc.date.accessioned2014-12-12T13:42:01Z
dc.date.available2014-12-12T13:42:01Z
dc.date.issued2014-11
dc.identifier.citationVickers , M A , Wilkie , G M , Robinson , N , Rivera , N , Haque , T , Crawford , D H , Barry , J , Fraser , N , Turner , D M , Robertson , V , Dyer , P , Flanagan , P , Newlands , H R , Campbell , J & Turner , M 2014 , ' Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease ' British Journal of Haematology , vol. 167 , no. 3 , pp. 402-410 . https://doi.org/10.1111/bjh.13051en
dc.identifier.issn0007-1048
dc.identifier.otherPURE: 45030285
dc.identifier.otherPURE UUID: 56bcc831-01e9-4d35-b623-99863d757c5f
dc.identifier.otherScopus: 84912035006
dc.identifier.urihttp://hdl.handle.net/2164/4107
dc.descriptionFunded by Wellcome Trust Translational Award SNBTSen
dc.format.extent9en
dc.language.isoeng
dc.relation.ispartofBritish Journal of Haematologyen
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/3.0/en
dc.subjectcell therapyen
dc.subjectEpstein-Barr virusen
dc.subjectcytotoxicityen
dc.subjectlymphoproliferative diseaseen
dc.subjectRC Internal medicineen
dc.subjectWellcome Trusten
dc.subject102610en
dc.subject.lccRCen
dc.titleEstablishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative diseaseen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen, Applied Medicineen
dc.contributor.institutionUniversity of Aberdeen, Institute of Medical Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1111/bjh.13051


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record